Extended treatment for cigarette smoking cessation: A randomized control trial. Addiction Laude, J. R., Bailey, S. R., Crew, E., Varady, A., Lembke, A., McFall, D., Jeon, A., Killen, D., Killen, J. D., David, S. P. 2017


To test the potential benefit of extending cognitive-behavioral therapy (CBT) relative to not extending CBT on long-term abstinence from smoking.Two-group parallel randomised controlled trial. Patients were randomized to receive non-extended CBT (n?=?111) or extended CBT (n?=?112) following a 26-week open-label treatment.Community clinic in the USA.219 smokers (mean age: 43?years; mean cigarettes/day: 18).All participants received 10?weeks of combined CBT?+?bupropion sustained release (bupropion SR)?+?nicotine patch and were continued on CBT and either no medications if abstinent, continued bupropion?+?nicotine replacement therapy (NRT) if increased craving or depression scores, or varenicline if still smoking at 10?weeks. Half of participants were randomized at 26?weeks to extended CBT (E-CBT) through week 48 and half to non-extended CBT (no additional CBT sessions).The primary outcome was expired CO-confirmed, seven-day point-prevalence (PP) at 52-week and 104-week follow-up. Analyses were based on intention-to-treat.PP-abstinence rates at the 52-week follow-up were comparable across non-extended CBT (40%) and E-CBT (39%) groups [OR 0.99; 95% CI (0.55,1.78)]. A similar pattern was observed across non-extended CBT (39%) and E-CBT (33%) groups at the 104-week follow-up [OR 0.79; 95% CI (0.44,1.40)].Prolonging cognitive-behavioral therapy from 26 to 48?weeks does not appear to improve long-term abstinence from smoking.

View details for DOI 10.1111/add.13806

View details for PubMedID 28239942